These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 2950715)
1. Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains. Goto S; Matsukado Y; Mihara Y; Inoue N; Miyamoto E Acta Neuropathol; 1986; 72(2):150-6. PubMed ID: 2950715 [TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease. Marshall PE; Landis DM; Zalneraitis EL Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034 [TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487 [TBL] [Abstract][Full Text] [Related]
4. [Parkinson's disease concurring with other diseases of the central nervous system]. Neumayer E Z Neurol; 1971; 199(4):306-18. PubMed ID: 4104834 [No Abstract] [Full Text] [Related]
5. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease. Utal AK; Stopka AL; Roy M; Coleman PD Neuroscience; 1998 Oct; 86(4):1055-63. PubMed ID: 9697113 [TBL] [Abstract][Full Text] [Related]
7. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders. Goto S; Hirano A; Rojas-Corona RR Acta Neuropathol; 1989; 78(5):543-50. PubMed ID: 2479214 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. Grafe MR; Forno LS; Eng LF J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185 [TBL] [Abstract][Full Text] [Related]
10. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516 [No Abstract] [Full Text] [Related]
11. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Goto S; Hirano A; Rojas-Corona RR Ann Neurol; 1989 Mar; 25(3):298-304. PubMed ID: 2543263 [TBL] [Abstract][Full Text] [Related]
12. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242 [TBL] [Abstract][Full Text] [Related]
13. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains. Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898 [TBL] [Abstract][Full Text] [Related]
14. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Glass M; Dragunow M; Faull RL Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533 [TBL] [Abstract][Full Text] [Related]
15. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Huot P; Lévesque M; Parent A Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832 [TBL] [Abstract][Full Text] [Related]
16. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain. Gulyás B; Sovago J; Gomez-Mancilla B; Jia Z; Szigeti C; Gulya K; Schumacher M; Maguire RP; Gasparini F; Halldin C Brain Struct Funct; 2015 Sep; 220(5):3043-51. PubMed ID: 24969128 [TBL] [Abstract][Full Text] [Related]
17. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study. Waeber C; Palacios JM Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301 [TBL] [Abstract][Full Text] [Related]
18. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. Perry TL; Hansen S; Kloster M N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566 [No Abstract] [Full Text] [Related]
19. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088 [TBL] [Abstract][Full Text] [Related]
20. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes. Marshall PE; Landis DM Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]